Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Treating Pediatric Patients With Positive Cytomegalovirus Undergoing Donor Stem Cell Transplant

Cytomegaloviral Infection Clinical Trial

Official title:

A Phase 1/2 Clinical Study to Evaluate the Optimal Dose and the Protective Effect of CMV-MVA Triplex Vaccine in Pediatric Patients Receiving an Allogeneic Hematopoietic Stem Cell Transplant

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03354728
• Other study ID #: 17236
• Secondary ID: NCI-2017-0204617
• Status: Recruiting
• Phase: Phase 1/Phase 2
• Start date: May 11, 2018
• Est. completion date: November 11, 2024

Study information

• Verified date: September 2023
• Source: City of Hope Medical Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This phase I/II trial studies the side effects and best dose of multi-antigen cytomegalovirus (CMV)-modified vaccinia ankara vaccine and to see how well it works in treating pediatric patients with positive cytomegalovirus who are undergoing donor stem cell transplant. Multi-antigen CMV-modified vaccinia ankara vaccine may help people resist CMV life-threatening complications.

Description:

PRIMARY OBJECTIVES:

I. To investigate the optimal dose of multi-antigen CMV-modified vaccinia ankara vaccine (Triplex) in CMV-positive pediatric patients receiving human leukocyte antigen (HLA) matched, mismatched, or haploid-identical hematopoietic cell transplantation (HCT). (Phase I) II. To evaluate the safety profile of Triplex in this patient population. (Phase I) III. To determine if Triplex reduces the frequency of CMV events when compared to historical data. (Phase II)

SECONDARY OBJECTIVES:

I. To characterize CMV reactivation and disease by assessing: time to CMV reactivation, duration of viremia, recurrence of viremia, incidence of late CMV viremia/disease (defined as > 100 days and =< 365 days post HCT), use of anti-viral drugs triggered by rising CMV viremia or viremia >= 3750 IU/mL, cumulative number of CMV specific antiviral treatment days.

II. To evaluate the impact of Triplex on transplant related outcomes by assessing the incidence of acute and chronic graft versus host disease (GVHD), relapse, non-relapse mortality (NRM), all-cause mortality, infections.

III. To investigate the impact of Triplex on cellular immunity by investigating: the level, function and kinetics of CMV-specific T-cell immunity, the changes in adaptive natural killer (NK) cell population and highly cytotoxic memory NKG2C+ NK cells, and changes in GVHD biomarkers.

OUTLINE: This is a phase I, dose-escalation study followed by a phase II study.

Patients receive multi-antigen CMV-modified vaccinia ankara vaccine intramuscularly (IM) on days 28 and 56 post-HCT.

After completion of study treatment, patients are followed up for up to 270 or 365 days.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 80
• Est. completion date: November 11, 2024
• Est. primary completion date: November 11, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 1 Year to 21 Years

Eligibility

Inclusion Criteria:

• All subjects (or their guardians) must have the ability to understand and the willingness to sign a written informed consent; age appropriate assent will be obtained per institutional guidelines; to allow non-English patients to participate in this study, bilingual health services will be provided in the appropriate language when feasible

• Participant must be willing to comply with study and/or follow-up procedures, including willingness to be followed for one year post-HCT

• Planned allogenic (allo)-HCT, with 9/10 or 10/10 (A, B, C, DRB1, DQB1) high/intermediate resolution HLA donor allele matching and with no T-cell depletion of graft

• Planned related HCT with molecular 3/6 HLA donor allele matching (haploidentical) (for phase I only)

• CMV seropositive at the time of HCT

• Conditioning and immunosuppressive regimens according to institutional guidelines are permitted

• Negative serum or urine beta-human chorionic gonadotropin (HCG) test (female patient of childbearing potential only) within two weeks of registration

• Seronegative for human immunodeficiency virus (HIV), hepatitis C virus (HCV); if hepatitis B virus (HBV) core seropositive, absence of HBV deoxyribonucleic acid (DNA) within 2 months of registration

• Agreement by females of childbearing potential and sexually active males to use an effective method of contraception (hormonal or barrier method of birth control or abstinence) prior to study entry and for up to 90 days post-HCT; should a woman become pregnant or suspect that she is pregnant while participating on the trial, she should inform her treating physician immediately

Exclusion Criteria:

• TRANSPLANT RELATED CRITERIA: Patients undergoing cord blood transplant (CB-HCT)

• Any prior investigational CMV vaccine

• Anti-CMV therapy in the last 6 months

• Live attenuated vaccines

• Medically indicated subunit (Engerix-B for HBV; Gardasil for human papillomavirus [HPV]) or killed vaccine (e.g. influenza, pneumococcal)

• Allergy treatment with antigens injections

• Alemtuzumab, cyclophosphamide, ATG or any equivalent in vivo T-cell depleting agent; Note: Pre-transplant ATG is permitted

• Antiviral medications with known therapeutic effects on CMV such as ganciclovir (GCV)/valine (VAL), FOS, Cidofovir, CMX-001, maribavir; acyclovir has no known therapeutic efficacy against CMV and is allowable as standard of care to prevent herpes simplex virus (HSV)

• Prophylactic therapy with CMV immunoglobulin or prophylactic antiviral CMV treatment; intravenous immunoglobulin therapy (IVIG) is allowed

• Other investigational product-concurrent enrollment in other clinical trials using any investigational new drug (IND) drugs with unknown effects on CMV or with unknown toxicity profiles is prohibited

• Other medications that might interfere with the evaluation of the investigational product

• Patients with congenital immune deficiency

• Patients with active autoimmune conditions requiring systemic immunosuppressive therapy within the previous 5 years are not eligible, the exception to this is patients with aplastic anemia, who are eligible

• Pregnant women and women who are lactating; CMV-MVA Triplex risks to pregnant women are unknown; because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with the administered vaccine, also breastfeeding should be discontinued if the mother is enrolled on this study

• Any other condition that would, in the investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns or compliance with clinical study procedures, e.g., social/psychological issues, etc

• Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issue related to feasibility/logistics)

Related Conditions & MeSH terms

• Cytomegaloviral Infection
• Cytomegalovirus Infections
• Hematopoietic Cell Transplant Recipient

Intervention

Other:
• Laboratory Biomarker Analysis
Correlative studies

Biological:
• Multi-peptide CMV-Modified Vaccinia Ankara Vaccine
Given IM

Locations

Country	Name	City	State
United States	City of Hope Medical Center	Duarte	California

Sponsors (2)

Lead Sponsor	Collaborator
City of Hope Medical Center	National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Optimal dose (Phase I)		Up to 1 year
Primary	Incidence of adverse events (Phase I)	Adverse events will be characterized using the descriptions and grading scales according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.	Up to 1 year
Primary	Cytomegalovirus (CMV) events (reactivation >= 1250 IU/mL), or viremia treated by anti-viral therapy, or detection of CMV by histology (Phase II)	Will be assessed with exact 90% confidence bounds.	Prior to day 100 post-hematopoietic cell transplantation (HCT) or viremia treated by anti-viral therapy, or detection of CMV by histology
Primary	Non-relapse mortality	Will be compared to historical controls at the final analysis, and a 90% lower confidence bound on the difference in 12-month event free survival will be produced.	At 100 days post-HCT
Primary	Severe (grade 3-4) acute graft versus host disease (aGVHD)		Within 2 weeks from each vaccination
Primary	Incidence of grade 3-4 adverse events	Will be graded per CTCAE version 4.0.	Within 2 weeks from each vaccination
Secondary	Time-to viremia		Number of days from transplant to the date of > 1250 IU/mL, assessed up to 1 year
Secondary	Duration of viremia		Up to 1 year
Secondary	Incidence of late CMV viremia		> 100 and =< 365 days post-HCT
Secondary	Use of antiviral drugs (triggered by rising CMV viremia or viremia >= 3,750 IU/ml)		Up to 1 year, rising CMV viremia or viremia >= 3,705
Secondary	Cumulative number of CMV specific antiviral treatment days		Up to 1 year
Secondary	Time to engraftment		Up to 1 year
Secondary	Incidence of acute graft versus host disease (aGVHD)		Up to 1 year
Secondary	Chronic GVHD (cGVHD)		Up to 1 year
Secondary	Relapse defined by bone marrow and/or imaging studies		Up to 1 year
Secondary	Non-relapse mortality		Up to 1 year
Secondary	All-cause mortality		Up to 1 year
Secondary	Infections		Up to 1 year
Secondary	Levels of CMV-specific T cell immunity	Will be combined with immunophenotyping and functional studies. The data analysis for estimating the effect of vaccination on cellular immunity will necessarily be more exploratory in nature. The longitudinal CMV-specific cellular assay data will be modeled on a logarithmic scale, using a generalized estimating equation approach to accommodate the stochastic dependence through time. This produces an estimated multiplicative effect of vaccination, qualified by a valid estimate of variability.	Up to 1 year post-HCT
Secondary	Kinetics of CMV-specific T cell immunity	The data analysis for estimating the effect of vaccination on cellular immunity will necessarily be more exploratory in nature. The longitudinal CMV-specific cellular assay data will be modeled on a logarithmic scale, using a generalized estimating equation approach to accommodate the stochastic dependence through time. This produces an estimated multiplicative effect of vaccination, qualified by a valid estimate of variability.	Up to 1 year post-HCT
Secondary	Natural killer (NK) phenotype	The data analysis for estimating the effect of vaccination on cellular immunity will necessarily be more exploratory in nature. The longitudinal CMV-specific cellular assay data will be modeled on a logarithmic scale.	Up to 1 year post-HCT
Secondary	NK function (cytotoxicity and cytokine production)	The data analysis for estimating the effect of vaccination on cellular immunity will necessarily be more exploratory in nature. The longitudinal CMV-specific cellular assay data will be modeled on a logarithmic scale, using a generalized estimating equation approach to accommodate the stochastic dependence through time. This produces an estimated multiplicative effect of vaccination, qualified by a valid estimate of variability.	Up to 1 year post-HCT